ERA-NET TRANSCAN-2: ALIGNING NATIONAL/ REGIONAL TRANSLATIONAL CANCER RESEARCH PROGRAMMES AND ACTIVITIES
TRANSCAN and TRANSCAN-2 Research Funding
Overview of the 2011-2017 Joint Transnational Calls’ Results
TRANSNATIONAL APPROACH to translational cancer research since 2011
Over a period of 11 years, a total funding of €85.2 million was awarded to 79 transnational research projects, including EU contribution of €3.4 million for a single co-financed call under the TRANSCAN-2 programme.
TOTAL INVESTMENTS in TRANSCAN and TRANSCAN-2
As a result of the seven calls, 79 research projects were financed, involving 406 principal investigators from 19 different countries.
Total investment, number of projects and principal investigators funded in seven cross-border calls
*Including EU contribution of €3.4 million
Distribution by gender of the 406 principal investigators involved in the 79 projects awarded in TRANSCAN and TRANSCAN-2
Within the framework of the three TRANSCAN calls, 30 projects were financed for an amount of 33 million euros, while within the framework of the four TRANSCAN-2 calls, 49 projects were financed for an amount of 52.2 million euros.
Number of participating funding organizations in TRANSCAN and TRANSCAN-2 calls
The average number of funding organizations that participated in the calls increased by 32% from TRANSCAN to TRANSCAN-2. This means a greater commitment from funding organizations and increased financial resources for translational cancer research over time.
SUBMITTED PROJECTS and SUCCESS RATE
The TRANSCAN and TRANSCAN-2 calls attracted a total of 2900 researchers that were involved in 561 pre-proposals submitted in the different calls. The overall success rate of submitted eligible pre-proposals averaged 15.3%.
Total number of submitted eligible pre-proposals and success rate in seven calls for proposals
*Including EU contribution, in the amount of EUR 3.4 million.
Ratio between submitted eligible pre-proposals and funded projects in TRANSCAN and TRANSCAN-2 calls
DISTRIBUTION of TOTAL INVESTMENT PER CALL TOPIC
NUMBER of TRANSCAN and TRANSCAN-2 FUNDED PROJECTS PER CANCER TYPE1
The majority of TRANSCAN and TRANSCAN-2 funded projects are focused on colorectal cancer and haematopoietic and lymphoid malignancies (16.4%), followed by breast (14%), and lung cancer (8.9%).
CLINICAL TRIALS in TRANSCAN and TRANSCAN-2 FUNDED PROJECTS
A total budget of EUR 33 million was spent in the calls 2011-2013. On average, 11 funding organisations participated in each call.
SPENT BUDGET in TRANSCAN FUNDED PROJECTS by COUNTRY (MILLION EUR)
The majority of TRANSCAN and TRANSCAN-2 funded projects are focused on colorectal cancer and haematopoietic and lymphoid malignancies (16.4%), followed by breast (14%), and lung cancer (8.9%).
TOTAL NUMBER of FUNDED PRINCIPAL INVESTIGATORS and COORDINATORS in TRANSCAN CALLS BY COUNTRY
SPENT BUDGET in TRANSCAN-2 FUNDED PROJECTS by COUNTRY (MILLION EUR)
A total budget of EUR 52.2 million was spent in the calls 2014-2017. Some countries (Italy, France, Netherlands, Spain and Norway) participated in the calls with more than one funding organisation. On average, 21 funding organisations participated in each call.
TOTAL NUMBER of FUNDED PRINCIPAL INVESTIGATORS and COORDINATORS in TRANSCAN-2 CALLS by COUNTRY
Achievements of TRANSCAN funding programme
TRANSCAN and TRANSCAN-2 research funding landscape demonstrates a strong support of the EU transnational collaboration aims. In the 7-year period, both networks have contributed significantly to supporting excellent science in the field of translational cancer research, with 7 calls, 85.2 million € were invested to fund 79 small- to mid-sized research consortia including 406 research groups.